H2RAH2-Receptor Antagonist
H2RAHistamine type-2 receptor antagonist (stomach acid)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
People with compromised kidney function might consider using an H2RA, if possible.
The researchers found that 72.4, 11.8, and 3.3 percent of children were prescribed an antibiotic, an H2RA, and a PPI, respectively.
Almost three-quarters (72.4%) had been prescribed an antibiotic, while 39,488 (11.8%) had been prescribed an H2RA and 11,089 (3.3%) a PPI.
The drugs segment is an established market offering antacids, PPIs, H2RAs and prokinetics.
Most cases were treated successfully with conservative treatment, such as avoiding further thermal insult (17%) and antisecretory treatment, such as PPIs (67%) and H2RAs (11%) or in combination with sucralfate suspension (33%) to prevent further injury from reflux gastric acid.
25 Food and Drugs Agency (FDA) issued a safety announcement of a possible increased risk of fractures of the hip, wrist, and spine with the use of PPIs.26 But why same observation was not seen in H2RA is probably because of more profound acid suppression by PPIs than H2RA.
Unlike Cimetidine, the first H2RA, Famotidine does not alter hepatic C-P450 drug metabolizing enzyme system and does not demonstrate interaction with other drugs [2].
* Histamine-receptor antagonists (H2RAs) like Pepcid and Zantac reduce the amount of acid your stomach produces.
Research recently published in JAMA has finally elucidated a link between the use of PPI and H2RA, and B12 deficiency.
Projected H2RA cost was based on ranitidine 150 mg twice daily (at $12 per month) for 9.3 months (comparable to time of PPI use in 2009) as initial anti-secretory agent (instead of PPI) in those with mild to moderate heartburn/UGI symptoms (estimated at 40% of total based on our data and others), (23-25) and estimated response rate of 55%.
After the marketing of the first H2-receptor antagonists (H2RA) in the eighties a temporal consistency with the decrease was observed in PU incidence in Turkey.
The impact of taking any daily dosage of H2RA medications was less pronounced but also significant: 4.2 percent of patients with B12 deficiency used these medications versus 3.2 percent of control patients.